| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2025 | 700 | 1.990 |
Why?
|
| Influenza Vaccines | 9 | 2025 | 498 | 1.670 |
Why?
|
| Hospitalization | 26 | 2025 | 1902 | 1.520 |
Why?
|
| Intubation, Intratracheal | 11 | 2025 | 289 | 1.380 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2025 | 189 | 1.090 |
Why?
|
| Laryngoscopes | 5 | 2025 | 71 | 0.930 |
Why?
|
| Respiratory Syncytial Virus Infections | 5 | 2025 | 377 | 0.830 |
Why?
|
| Critical Illness | 8 | 2024 | 618 | 0.810 |
Why?
|
| Vaccination | 12 | 2025 | 1018 | 0.810 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2019 | 4 | 0.630 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 20 | 0.620 |
Why?
|
| Bronchoscopy | 5 | 2019 | 174 | 0.620 |
Why?
|
| Pneumonia | 2 | 2022 | 334 | 0.600 |
Why?
|
| Laryngoscopy | 4 | 2025 | 161 | 0.590 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 46 | 0.590 |
Why?
|
| Respiration, Artificial | 5 | 2023 | 504 | 0.510 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 251 | 0.500 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2025 | 123 | 0.500 |
Why?
|
| Heart Arrest | 4 | 2025 | 375 | 0.500 |
Why?
|
| Adult | 43 | 2025 | 31600 | 0.490 |
Why?
|
| Pleurisy | 1 | 2015 | 6 | 0.480 |
Why?
|
| Aged | 35 | 2025 | 21456 | 0.480 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 4 | 0.470 |
Why?
|
| Time | 1 | 2015 | 99 | 0.470 |
Why?
|
| Humans | 79 | 2025 | 132201 | 0.450 |
Why?
|
| Risk Assessment | 3 | 2015 | 3736 | 0.450 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 29 | 0.450 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 2 | 2025 | 71 | 0.440 |
Why?
|
| Middle Aged | 36 | 2025 | 29007 | 0.440 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 43 | 0.430 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 176 | 0.410 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2019 | 234 | 0.400 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2165 | 0.390 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2012 | 8 | 0.390 |
Why?
|
| United States | 22 | 2025 | 11675 | 0.380 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 229 | 0.380 |
Why?
|
| Hypoxia | 2 | 2024 | 259 | 0.350 |
Why?
|
| Pneumonectomy | 1 | 2012 | 148 | 0.340 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 479 | 0.340 |
Why?
|
| Female | 41 | 2025 | 70754 | 0.340 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 3091 | 0.340 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2023 | 233 | 0.340 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2019 | 83 | 0.340 |
Why?
|
| Cardiopulmonary Resuscitation | 2 | 2025 | 334 | 0.330 |
Why?
|
| Intensive Care Units | 4 | 2025 | 525 | 0.330 |
Why?
|
| Shock | 2 | 2022 | 99 | 0.330 |
Why?
|
| Influenza B virus | 3 | 2025 | 100 | 0.330 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 33 | 0.320 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 569 | 0.320 |
Why?
|
| Seasons | 4 | 2025 | 328 | 0.300 |
Why?
|
| Case-Control Studies | 8 | 2025 | 3414 | 0.300 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 307 | 0.290 |
Why?
|
| Aged, 80 and over | 11 | 2025 | 7123 | 0.290 |
Why?
|
| Male | 32 | 2025 | 64979 | 0.290 |
Why?
|
| Influenza A virus | 2 | 2025 | 152 | 0.250 |
Why?
|
| Legionnaires' Disease | 2 | 2017 | 8 | 0.240 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 170 | 0.240 |
Why?
|
| Oseltamivir | 1 | 2025 | 19 | 0.240 |
Why?
|
| Diagnosis, Differential | 6 | 2019 | 1962 | 0.230 |
Why?
|
| Emergency Service, Hospital | 4 | 2025 | 1171 | 0.220 |
Why?
|
| Genital Neoplasms, Female | 1 | 2024 | 45 | 0.220 |
Why?
|
| Bias | 1 | 2024 | 144 | 0.210 |
Why?
|
| Emergency Medicine | 1 | 2025 | 163 | 0.210 |
Why?
|
| Polysomnography | 3 | 2019 | 155 | 0.210 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 93 | 0.210 |
Why?
|
| Hemoptysis | 2 | 2021 | 22 | 0.200 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 111 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 104 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2679 | 0.190 |
Why?
|
| Paclitaxel | 1 | 2003 | 140 | 0.190 |
Why?
|
| Prospective Studies | 8 | 2025 | 6569 | 0.190 |
Why?
|
| Respiratory Paralysis | 1 | 2001 | 6 | 0.190 |
Why?
|
| Pulmonary Atelectasis | 1 | 2001 | 14 | 0.180 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 9 | 0.180 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 234 | 0.180 |
Why?
|
| Hospital Mortality | 5 | 2025 | 1081 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 39 | 0.180 |
Why?
|
| Sentinel Surveillance | 3 | 2025 | 24 | 0.180 |
Why?
|
| Fluid Therapy | 1 | 2022 | 147 | 0.180 |
Why?
|
| Adolescent | 10 | 2025 | 20557 | 0.180 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 113 | 0.180 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 414 | 0.170 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 322 | 0.170 |
Why?
|
| Hypotension | 1 | 2022 | 185 | 0.170 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2001 | 127 | 0.170 |
Why?
|
| Aneurysm | 1 | 2021 | 82 | 0.160 |
Why?
|
| Young Adult | 9 | 2025 | 9965 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 291 | 0.160 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2019 | 4 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 79 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2022 | 180 | 0.160 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 1161 | 0.160 |
Why?
|
| Aneurysm, False | 1 | 2021 | 93 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2025 | 823 | 0.160 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 57 | 0.160 |
Why?
|
| Mediastinitis | 2 | 2017 | 16 | 0.150 |
Why?
|
| Azithromycin | 1 | 2019 | 43 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2021 | 368 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 119 | 0.150 |
Why?
|
| Cough | 1 | 2019 | 96 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 462 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 899 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2002 | 408 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 1250 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2019 | 373 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2025 | 1079 | 0.140 |
Why?
|
| Home Care Services | 1 | 2018 | 75 | 0.140 |
Why?
|
| Video Recording | 3 | 2025 | 204 | 0.140 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 32 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2017 | 72 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2003 | 1304 | 0.130 |
Why?
|
| Fever | 1 | 2019 | 310 | 0.130 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 49 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 628 | 0.130 |
Why?
|
| CA-125 Antigen | 1 | 1996 | 15 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2017 | 110 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 926 | 0.120 |
Why?
|
| Bacteremia | 1 | 2020 | 428 | 0.120 |
Why?
|
| Abdominal Neoplasms | 1 | 1996 | 31 | 0.120 |
Why?
|
| Oxygen | 3 | 2024 | 569 | 0.120 |
Why?
|
| Machine Learning | 1 | 2019 | 348 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1461 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 152 | 0.120 |
Why?
|
| Carmine | 1 | 1995 | 1 | 0.120 |
Why?
|
| Leiomyoma | 1 | 1996 | 83 | 0.120 |
Why?
|
| Parasitic Diseases | 1 | 1996 | 60 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2553 | 0.120 |
Why?
|
| Logistic Models | 2 | 2021 | 1841 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 1995 | 22 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 40 | 0.110 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 78 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 246 | 0.110 |
Why?
|
| Legionella | 1 | 2014 | 9 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 259 | 0.110 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2025 | 153 | 0.110 |
Why?
|
| Immunization Schedule | 2 | 2025 | 107 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2017 | 425 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 178 | 0.100 |
Why?
|
| Lung | 3 | 2014 | 1556 | 0.100 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 39 | 0.100 |
Why?
|
| Algorithms | 1 | 2019 | 1723 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1541 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 1255 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 565 | 0.090 |
Why?
|
| Trachea | 2 | 2023 | 210 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2020 | 17391 | 0.090 |
Why?
|
| Electronic Health Records | 3 | 2024 | 802 | 0.090 |
Why?
|
| Prognosis | 3 | 2019 | 5015 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 312 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 1363 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 1554 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 2313 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2398 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 552 | 0.080 |
Why?
|
| Biopsy | 1 | 2012 | 1287 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2024 | 5173 | 0.070 |
Why?
|
| Treatment Outcome | 7 | 2025 | 13028 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1258 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 5410 | 0.060 |
Why?
|
| Sleep | 2 | 2019 | 373 | 0.060 |
Why?
|
| Cyclophosphamide | 2 | 2004 | 426 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2004 | 1574 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2004 | 97 | 0.050 |
Why?
|
| Masks | 1 | 2024 | 40 | 0.050 |
Why?
|
| Vincristine | 1 | 2004 | 196 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 67 | 0.050 |
Why?
|
| Bronchial Diseases | 1 | 2003 | 12 | 0.050 |
Why?
|
| Platinum | 1 | 2003 | 13 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 223 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 303 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2002 | 6 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 6452 | 0.050 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2002 | 11 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2022 | 85 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2001 | 3 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 32 | 0.050 |
Why?
|
| Sarcoma | 1 | 2004 | 207 | 0.050 |
Why?
|
| Heart Septum | 1 | 2001 | 55 | 0.050 |
Why?
|
| Immunization | 1 | 2023 | 312 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 141 | 0.040 |
Why?
|
| Hospitals | 1 | 2024 | 439 | 0.040 |
Why?
|
| Viral Load | 1 | 2023 | 408 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 749 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2003 | 200 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1304 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2022 | 137 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2023 | 565 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 242 | 0.040 |
Why?
|
| Diaphragm | 1 | 2001 | 98 | 0.040 |
Why?
|
| Patient Selection | 1 | 2024 | 731 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 22 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 3632 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 298 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 956 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 225 | 0.040 |
Why?
|
| Subclavian Artery | 1 | 2021 | 70 | 0.040 |
Why?
|
| Enterococcus | 1 | 2020 | 31 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 239 | 0.040 |
Why?
|
| Angiography | 1 | 2021 | 208 | 0.040 |
Why?
|
| Prevalence | 2 | 2023 | 2663 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2001 | 153 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 553 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 38 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1175 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 893 | 0.040 |
Why?
|
| Heart Atria | 1 | 2001 | 337 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2003 | 336 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 2920 | 0.040 |
Why?
|
| Vancomycin | 1 | 2020 | 222 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1653 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2003 | 816 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1175 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 559 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2022 | 1233 | 0.030 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 31 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 261 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 671 | 0.030 |
Why?
|
| Ileal Neoplasms | 1 | 1997 | 6 | 0.030 |
Why?
|
| Legionella pneumophila | 1 | 2017 | 6 | 0.030 |
Why?
|
| Fallopian Tube Diseases | 1 | 1997 | 8 | 0.030 |
Why?
|
| Intestinal Fistula | 1 | 1997 | 29 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1348 | 0.030 |
Why?
|
| Critical Care | 1 | 2002 | 687 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 442 | 0.030 |
Why?
|
| Metapneumovirus | 1 | 2017 | 52 | 0.030 |
Why?
|
| Length of Stay | 2 | 2017 | 1382 | 0.030 |
Why?
|
| Ileal Diseases | 1 | 1997 | 28 | 0.030 |
Why?
|
| Fistula | 1 | 1997 | 54 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3760 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 175 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 262 | 0.030 |
Why?
|
| Stents | 2 | 2017 | 874 | 0.030 |
Why?
|
| Risk Factors | 3 | 2024 | 10944 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 697 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1186 | 0.030 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1995 | 23 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2230 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 381 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1995 | 76 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 22 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 3377 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 324 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 821 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2014 | 45 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1520 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 181 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 103 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 576 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 325 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 34842 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1444 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 3015 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 564 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1995 | 1714 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3139 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1997 | 1018 | 0.020 |
Why?
|
| Ohio | 1 | 2006 | 85 | 0.020 |
Why?
|
| Sleep, REM | 1 | 2006 | 23 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2006 | 212 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 272 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2006 | 306 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2006 | 212 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 396 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 50 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 160 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 313 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 444 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 673 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 1444 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1295 | 0.010 |
Why?
|
| Adnexal Diseases | 1 | 1997 | 23 | 0.010 |
Why?
|